Arthneeti
All Q1 FY27 results →
DC

Dishman Carbogen Amcis Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹150
Market cap₹2.3K Cr
P/E129.5
Updated16 Oct 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
FundraiseFundraise planned

The short version

FY27 revenue expected to grow by at least 30-35% for the Indian entity (Page 19). FY27 revenue expected to see single-digit growth, with EBITDA margin similar to or slightly higher than last year.

From Dishman Carbogen Amcis Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Moderate growth
  • FY27 revenue expected to grow by at least 30-35% for the Indian entity (Page 19).
  • Overall company expects single-digit revenue growth for FY27 due to deferral of some orders and market conditions (Page 9).
  • FY28-29 outlook anticipates substantial growth across India operations, Swiss CDMO, and French injectables plant (Page 10).
  • Expectation of more than 10% year-on-year revenue growth in FY28-29 (Page 10).
  • Double-digit growth forecasted for French and Indian entities during FY28-29 (Page 10).
  • New tech transfers from Switzerland to India and advanced discussions on more transfers support growth (Page 19).

2 more points from Dishman Carbogen Amcis Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Ongoing co-investment with a Japanese customer: The second co-investment is expected to be completed during the next calendar year, adding capacity to provide more quantities to the customer (Page 25).
  • External Commercial Borrowing (ECB): Approved by RBI to raise funds at promoter entity level, which will be infused in the Indian entity primarily to prepay high-cost debt and finance future CapEx and working capital requirements (Pages 10, 14, 15).
  • CapEx of CHF 4.9 million incurred in Q1 FY27 (Page 9).

2 more points from Dishman Carbogen Amcis Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Order income is picking up, though market pressure continues (Page 5).
  • Several big pharma audits resulted in positive outcomes, leading to acquisition of new projects (Page 5).
  • Over 13 late phase projects, including PPQ campaigns, in portfolio with multiple Phase II projects successfully transformed into late phase programs (Page 5).
  • More RFPs (Requests for Proposals) are being received, indicating increased interest, but revenue translation may extend into next financial year (Page 21).
  • Co-investment with Japanese clients progressing, expected completion next calendar year to provide additional capacity (Page 25).

2 more points from Dishman Carbogen Amcis Ltd's call on order book

Create a free account to keep reading this call

Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹851 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Dishman Carbogen's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dishman Carbogen Amcis Ltd Q1 FY27 results?

FY27 revenue expected to grow by at least 30-35% for the Indian entity (Page 19). FY27 revenue expected to see single-digit growth, with EBITDA margin similar to or slightly higher than last year.

What is Dishman Carbogen Amcis Ltd share price analysis?

Dishman Carbogen Amcis Ltd currently shows a below-average growth signal. The stock trades at a P/E of 129.5 with a market cap of ₹2,349 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dishman Carbogen Amcis Ltd planning capital expenditure?

Ongoing co-investment with a Japanese customer: The second co-investment is expected to be completed during the next calendar year, adding capacity to provide more quantities to the customer (Page 25).

Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.